Breakthroughs, discoveries, and DIY tips sent six days a week. Terms of Service and Privacy Policy. Cancer follows a fairly standard protocol: Cells multiply out of ...

Discover how OS Therapies' immunotherapy, OST-HER2, originally developed for canine osteosarcoma, shows promising results in fast-tracking treatments for human osteosarcoma. Learn about comparative ...

According to DelveInsight's analysis, the market size for osteosarcoma in the 7MM is expected to grow significantly by 2034. As per DelveInsight estimates, the total incident population of ...

By combining imaging and therapy in one targeted approach, researchers hope to select patients who will benefit from the targeted radiation and strike tumors more accurately, while overcoming the ...

OS Therapies’ cancer vaccine, OST-HER2, has been shown to significantly improve overall survival (OS) in patients with recurrent, fully resected, pulmonary metastatic osteosarcoma after two years.

While genetic sequencing has previously helped to uncover different subtypes of other cancers, like breast or skin cancer, for which those patients then receive targeted treatment personalised to ...

Osteosarcoma is a malignant neoplasm of the bone and is the most common histological form of primary bone cancer. It is most prevalent in children and young adults, as it is associated with the ...

For children and young adults diagnosed with osteosarcoma, a common type of bone cancer for that age group, the odds of survival can be devastatingly low (20-30%) when the disease spreads to the lungs ...

While osteosarcoma, the most common type of cancer that starts in the bone, is rare, the consequences can be devastating. About 800 new cases of osteosarcoma are diagnosed in the United States each ...

You don’t often hear people say that losing a limb is the best thing that could have happened. But LaQuinta Haynes, 36, of Canal Winchester, says losing her leg to cancer wasn’t an ending — it was the ...